Oral orforglipron is non-inferior to insulin glargine for cardiovascular events in type 2 diabetes

Design

Phase 3, event-driven, randomised, open-label, non-inferiority

Population

2749 adults with type 2 diabetes and cardiovascular or kidney disease

Primary outcome

Time to 4-point MACE

Effect

4.2% vs 5.0%; HR 0.84 (95% CI 0.59–1.20)

ACHIEVE-4 was an event-driven, open-label, phase 3 trial in 2749 adults with type 2 diabetes, overweight or obesity and established cardiovascular or chronic kidney disease, uncontrolled on up to three oral agents. They were randomised to once-daily oral orforglipron, a non-peptide GLP-1 receptor agonist, or titrated insulin glargine.

Over a median of two years, four-point major adverse cardiovascular events occurred in 4.2% on orforglipron and 5.0% on glargine (HR 0.84, 95% CI 0.59–1.20), meeting the prespecified non-inferiority margin of 1.8. Gastrointestinal adverse events affected 62.1% on orforglipron against 14.2% on glargine and were the commonest reason for stopping. Clinically significant hypoglycaemia was much less frequent with orforglipron (6.8% vs 19.2%).

This establishes cardiovascular safety, not benefit. Injectable semaglutide and liraglutide have outcome trials showing reduced events; orforglipron has not shown that. Its appeal is as a tablet without food or water timing rules. Regulatory status in India is not established here.

• Orforglipron met a safety threshold against insulin; it has not shown cardiovascular benefit.
• For patients with established cardiovascular disease, a GLP-1 agonist with proven outcome benefit remains the evidence-based choice.
• Expect gastrointestinal effects in most patients starting it; titrate slowly.
• Fewer hypoglycaemic episodes than insulin makes it worth weighing where hypoglycaemia is the main barrier.

Why it matters

An oral incretin that does not need injection or fasting rules could reach far more patients, if its safety holds.

Don't overread it

A non-inferiority margin of 1.8 rules out a large harm, not a modest one, and does not show benefit.

The statistics, in plain English

Non-inferiority was declared because the upper limit of the confidence interval (1.20) fell below 1.8. The interval includes both a 41% reduction and a 20% increase in events, so it cannot be read as showing fewer events.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.